Pancreatic Cancer Research

ResearcherUniversity of CambridgeActive in the last 2 years

Pippa G. Corrie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4875-7021; OpenAlex author ID A5060129800. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 4)
Trials
1
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 17

  1. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  2. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Last author DOI 10.1016/j.ejca.2024.114236↗
  3. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Last author DOI 10.1038/s41416-023-02170-9↗
  4. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2↗
  5. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  6. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  7. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  8. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  9. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Co-author DOI 10.1016/j.pan.2018.09.012↗
  10. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Last author DOI 10.2217/fon-2017-0338↗
  11. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. Last author DOI 10.1136/jclinpath-2014-202521↗
  12. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Co-author DOI 10.1159/000439171↗
  13. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patie… Co-author DOI 10.1007/s00262-013-1502-y↗
  14. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  15. "It can't be very important because it comes and goes"--patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative stud… Co-author DOI 10.1136/bmjopen-2013-004215↗
  16. Inspired to improve outcomes in pancreatic cancer. Interviewed by Natasha Galukande. Co-author DOI 10.2217/fon.13.45↗
  17. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Co-author DOI 10.1016/j.pan.2011.12.009↗

Trials 1

  1. Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors NCT00602082↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 6 shared papers, 2014–2023 · strength 0.50
  2. Somnath Mukherjee · 5 shared papers, 2018–2024 · strength 0.49
  3. Ganesh Radhakrishna · 4 shared papers, 2019–2024 · strength 0.43
  4. M. Hawkins · 4 shared papers, 2019–2024 · strength 0.43
  5. Christopher Mark Jones · 3 shared papers, 2020–2024 · strength 0.35
  6. D. Holyoake · 3 shared papers, 2020–2024 · strength 0.35
  7. Bristi Basu · 3 shared papers, 2015–2023 · strength 0.30
  8. David J. Propper · 3 shared papers, 2014–2025 · strength 0.29
  9. Duncan Ian Jodrell · 3 shared papers, 2012–2023 · strength 0.27
  10. Daniel H. Palmer · 3 shared papers, 2020–2021 · strength 0.27
  11. Alimu Dayimu · 2 shared papers, 2020–2023 · strength 0.24
  12. Tim Maughan · 2 shared papers, 2019–2024 · strength 0.24
  13. Chris N Hurt · 2 shared papers, 2019–2024 · strength 0.24
  14. Eric E. O’Neill · 2 shared papers, 2019–2024 · strength 0.24
  15. Harpreet Singh Wasan · 2 shared papers, 2020–2024 · strength 0.23
  16. James S. Good · 2 shared papers, 2020–2021 · strength 0.19
  17. Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
  18. Derek B. Grose · 2 shared papers, 2020–2021 · strength 0.19
  19. Katharine L. Aitken · 2 shared papers, 2020–2021 · strength 0.19
  20. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.19
  21. Christine Hughes · 1 shared paper, 2025 · strength 0.19
  22. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.19
  23. Debashis Sarker · 1 shared paper, 2025 · strength 0.19
  24. Claude Chelala · 1 shared paper, 2025 · strength 0.19
  25. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.